ch.oddb.org 
German | English | French
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Home<List for "A16AB" (43)–Sort according to Concentration, Size and Price
     ProductPackage SizeEFPCPSBDCCompositionRegistr. HolderCategory  
Imiglucerase (A16AB02) 1 products WHO-DDD DrugBank.ca 
  IP  Cerezyme 400 UDurchstechflasche(n)1511.851660.6510 %poudre pour solution à diluer pour perfusion: Imiglucerasum 400 USanofi-Aventis
(Suisse) SA		B / SLG
Agalsidase Alfa (A16AB03) 1 products WHO-DDD DrugBank.ca 
  IPCI ReplagalDurchstechflasche(n)1787.891960.8510 %Concentrate for infusion: Agalsidasum Alfa 1 mgTakeda Pharma AGA / SLG
Agalsidase Beta (A16AB04) 2 products WHO-DDD DrugBank.ca 
 SIPIP  Fabrazyme 5 mg 478.32536.6010 %poudre pour solution à diluer pour perfusion: Agalsidasum Beta 5 mgSanofi-Aventis
(Suisse) SA		A / SLG
 SIPIPCI Fabrazyme 35 mgDurchstechflasche(n)3348.273657.8510 %poudre pour solution à diluer pour perfusion: Agalsidasum Beta 35 mgSanofi-Aventis
(Suisse) SA		A / SLG
Alglucosidase Alfa (A16AB07) 2 products WHO-DDD DrugBank.ca 
LSIPIP  MyozymeDurchstechflasche(n)484.34514.3510 %Poudre pour solution à diluer pour perfusion: Alglucosidasum Alfa 50 mgSanofi-Aventis
(Suisse) SA		A / SLG
 SIPIP  Myozyme25 Durchstechflasche(n)k.A.Poudre pour solution à diluer pour perfusion: Alglucosidasum Alfa 50 mgSanofi-Aventis
(Suisse) SA		AG
Galsulfase (A16AB08) 1 products WHO-DDD DrugBank.ca 
LSIPIP  NaglazymeDurchstechflasche(n) à 5 ml1329.671462.5010 %Concentrate for infusion: Galsulfasum 5 mgDRAC AGB / SLG
Idursulfase (A16AB09) 1 products WHO-DDD DrugBank.ca 
LSIPIPCI ElapraseDurchstechflasche(n)2474.872708.0010 %Concentrate for infusion: Idursulfasum 2 mg/mlTakeda Pharma AGA / SLG
Velaglucerase Alfa (A16AB10) 1 products WHO-DDD DrugBank.ca 
L IPCI VPRIV 400 UDurchstechflasche(n)1957.792145.6510 %Lyophilisate: Velaglucerasum Alfa 400 UTakeda Pharma AGB / SLG
Elosulfase Alfa (A16AB12) 1 products WHO-DDD DrugBank.ca 
  IP  Vimizim 5mg/5mlDurchstechflasche(n)k.A.Concentrate for infusion: Elosulfasum Alfa 5mg / 5mlDRAC AGBG
Asfotase Alfa (A16AB13) 20 products WHO-DDD DrugBank.ca 
  IPCIPPStrensiq 40 mg/ml12k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml12k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml12k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 100 mg/ml12k.A.Injection solution: Asfotasum Alfa 100 mg/mlAlexion Pharma GmbHAG
L IPCIPPStrensiq 40 mg/ml1210677.3711262.8010 %Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHA / SLG
L IPCIPPStrensiq 40 mg/ml1216609.2417348.9010 %Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHA / SLG
L IPCIPPStrensiq 40 mg/ml1223727.4924652.2010 %Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHA / SLG
L IPCIPPStrensiq 100 mg/ml1247454.9748996.6010 %Injection solution: Asfotasum Alfa 100 mg/mlAlexion Pharma GmbHA / SLG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml12k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 40 mg/ml12k.A.Injection solution: Asfotasum Alfa 40 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 100 mg/ml k.A.Injection solution: Asfotasum Alfa 100 mg/mlAlexion Pharma GmbHAG
  IPCIPPStrensiq 100 mg/ml k.A.Injection solution: Asfotasum Alfa 100 mg/mlAlexion Pharma GmbHAG
Sebelipase Alfa (A16AB14) 1 products WHO-DDD DrugBank.ca 
  IPCI Kanuma 2 mg/ml k.A.Concentrate for infusion: Sebelipasum Alfa 2 mg/mlAlexion Pharma GmbHBG
Velmanase Alfa (A16AB15) 3 products WHO-DDD DrugBank.ca 
  IP  Lamzede 10 mg k.A.Dry substance: Velmanasum Alfa 10 mgChiesi SAAG
  IP  Lamzede 10 mg5k.A.Dry substance: Velmanasum Alfa 10 mgChiesi SAAG
  IP  Lamzede 10 mg10k.A.Dry substance: Velmanasum Alfa 10 mgChiesi SAAG
Pegunigalsidase Alfa (A16AB20) 3 products WHO-DDD  
  IP  Elfabrio 20 mg/10 ml 1864.182043.8010 %Concentrate for infusion: Pegunigalsidasum Alfa 20mg / 10mlChiesi SAA / SLG
  IP  Elfabrio 20 mg/10 ml5k.A.Concentrate for infusion: Pegunigalsidasum Alfa 20mg / 10mlChiesi SAAG
  IP  Elfabrio 20 mg/10 ml10k.A.Concentrate for infusion: Pegunigalsidasum Alfa 20mg / 10mlChiesi SAAG
Avalglucosidase Alfa (A16AB22) 3 products WHO-DDD  
L IP  Nexviadyme 100 mg 988.961049.5510 %poudre pour solution à diluer pour perfusion: Avalglucosidasum Alfa 100 mgSanofi-Aventis
(Suisse) SA		A / SLG
  IP  Nexviadyme 100 mg5k.A.poudre pour solution à diluer pour perfusion: Avalglucosidasum Alfa 100 mgSanofi-Aventis
(Suisse) SA		AG
  IP  Nexviadyme 100 mg10k.A.poudre pour solution à diluer pour perfusion: Avalglucosidasum Alfa 100 mgSanofi-Aventis
(Suisse) SA		AG
Cipaglucosidase Alfa (A16AB23) 3 products WHO-DDD  
L IPCI Pombiliti 105 mg 1031.821096.0010 %Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Cipaglucosidasum Alfa 105 mgAmicus Therapeutics
Switzerland GmbH		A / SLG
L IPCI Pombiliti 105 mg1010318.2010894.2510 %Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Cipaglucosidasum Alfa 105 mgAmicus Therapeutics
Switzerland GmbH		A / SLG
  IPCI Pombiliti 105 mg25k.A.Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Cipaglucosidasum Alfa 105 mgAmicus Therapeutics
Switzerland GmbH		AG
 show caption
 
ATC-Browser | Drugs A-Z | Recent Registrations
2026 ©ywesee GmbH
Settings | Help | Login | Contact | Home